Dr. Rovin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
455 Pinellas St
Suite 320
Clearwater, FL 33756Phone+1 727-446-2273Fax+1 727-441-4966
Summary
- Dr. Joshua Rovin is board certified in thoracic and cardiac surgery, and in general surgery. He has extensive experience in valve repair, thoracic aortic surgery, valve sparing aortic root reconstruction, mitral valve treatment, minimally invasive surgery and advanced endovascular repair. Dr. Rovin is one of the founding members and director of the Morton Plant Hospital (MPH) Valve Clinic, whose team was the first in Tampa Bay to perform a transcatheter aortic valve replacement (TAVR) for patients with severe aortic stenosis and transcatheter (TMVR and MitraClip) treatments for mitral disease . He is also director of Transcatheter and Aortic Therapies at MPH.
Education & Training
- University of Virginia Medical Center2003 - 2005
- University of Virginia Medical CenterChief Residency, Surgery, 2002 - 2003
- University of Virginia Medical CenterResidency, Surgery, 1997 - 2002
- University of Virginia Medical CenterInternship, Surgery, 1996 - 1997
- University of Louisville School of MedicineClass of 1996
Certifications & Licensure
- VA State Medical License 1996 - 2026
- FL State Medical License 2005 - 2025
- American Board of Surgery Surgery
- American Board of Thoracic Surgery Thoracic and Cardiac Surgery
Awards, Honors, & Recognition
- Top MD Consumers Checkbook
- Fellow (FACS) American College of Surgeons
Clinical Trials
- PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk Start of enrollment: 2011 Mar 01
- Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI). Start of enrollment: 2012 Apr 01
- Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (The COAPT Trial) and COAPT CAS Start of enrollment: 2012 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsDecreasing pacemaker implantation rates with Evolut supra-annular transcatheter aortic valves in a large real-world registry.James E Harvey, Rishi Puri, Kendra J Grubb, Steven J Yakubov, Paul D Mahoney
Cardiovascular Revascularization Medicine. 2024-12-01 - Transcatheter Aortic Valve Implantation by Valve Type in Women With Small Annuli: Results From the SMART Randomized Clinical Trial.Didier Tchétché, Roxana Mehran, Daniel J Blackman, Ramzi F Khalil, Helge Möllmann
JAMA Cardiology. 2024-12-01 - Four-year outcomes after transcatheter or contemporary surgical aortic valve replacement from the Evolut Low Risk trial.Basel Ramlawi, G Michael Deeb, Mubashir Mumtaz, Tanvir Bajwa, Joshua D Rovin
The Journal of Thoracic and Cardiovascular Surgery. 2024-08-22
Journal Articles
- Five Year Outcomes from the US Pivotal Trial of Valiant Captivia Stent Graft for Blunt Aortic InjuryHimanshu J Patel, Ali Azizzadeh, Omaida C Velazquez, Joshua D Rovin, Joseph V Lombardi, Ali Khoynezhad, The Annals of Thoracic Surgery
Press Mentions
- Morton Plant Hospital Marks Five Years of Performing TAVR SurgeriesFebruary 7th, 2017
- TAVR as an Option for Intermediate-Risk Patients: Physicians RespondAugust 24th, 2016
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: